Barrington lowered the firm’s price target on U.S. Physical Therapy (USPH) to $98 from $108 and keeps an Outperform rating on the shares. U.S. Physical Therapy gave initial FY25 guidance for $88M-$93M in adjusted EBITDA, which was in line with the firm’s prior modeling, though it has brought its estimate down a bit with this report, the analyst tells investors after earnings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on USPH:
- U.S. Physical Therapy: Strong Financials and Strategic Growth Drive Buy Rating
- U.S. Physical Therapy Reports Strong 2024 Results
- U.S. Physical Therapy Reports Strong Growth Amid Challenges
- U.S. Physical Therapy price target lowered to $112 from $115 at BofA
- US Physical Therapy: Strong Growth Potential Despite Medicare Rate Challenges